Detection of relevant colonic neoplasms with PET/CT: promising accuracy with minimal CT dose and a standardised PET cut-off

Abstract
Objective: To determine the performance of FDG-PET/CT in the detection of relevant colorectal neoplasms (adenomas ≥ 10 mm, with high-grade dysplasia, cancer) in relation to CT dose and contrast administration and to find a PET cut-off. Methods: 84 patients, who underwent PET/CT and colonoscopy (n = 79)/sigmoidoscopy (n = 5) for 79/C2 6 + 5/C2 2 (484 colonic segments, were included in a retrospective study. The accuracy of low-dose PET/CT in detecting mass-positive segments was evaluated by ROC analysis by two blinded independent reviewers relative to contrast-enhanced PET/CT. On a per-lesion basis characteristic PET values were tested as cut-offs. Results: Low-dose PET/CT and contrast-enhanced PET/CT provide similar accuracies (area under the curve for the average ROC ratings 0.925 vs. 0.929, respectively). PET demonstrated all carcinomas (n = 23) and 83% (30/36) of relevant adenomas. In all carcinomas and adenomas with high-grade dysplasia (n = 10) the SUV\textsubscript{max} was ≥ 5. This cut-off resulted in a better per-segment sensitivity and negative predictive value (NPV) than the average PET/CT reviews (sensitivity: 89% vs. 82%; NPV: 99% vs. 98%). All other tested cut-offs were inferior to the SUV\textsubscript{max}. Conclusion: FDG-PET/CT provides promising accuracy for colorectal mass detection. Low dose and lack of iodine contrast in the CT component do not impact the accuracy. The PET cut-off SUV\textsubscript{max} ≥ 5 improves the accuracy.

Keywords Polyp · Colorectal cancer · PET/CT · Screening

Abbreviations
AUC area under the curve
CAD computer-aided detection
CUP cancer of unknown primary
CEA carcinoembryonic antigen
CTC computed tomography
colonography
MIP maximum intensity projection
MPR multiplanar reconstruction
MRC magnetic resonance colonography
FDG 2-[\textsuperscript{18}F]fluoro-2-deoxy-D-glucose (FDG)
PET/ CT positron emission tomography/ computed tomography
ROC receiver operating curve
SUV standardised uptake value
VOI volume of interest
Introduction

Colorectal cancer is a leading cause of morbidity and mortality worldwide [1], despite being curable if detected early and even preventable if dysplastic adenomas as their precursors are eliminated [2–4]. Thus, colorectal screening has been shown to reduce the risk of dying from colorectal cancer. Consequently, colonoscopy was recommended early on for colorectal screening [5]. In 1996 computed tomography colonography (CTC) [6] and in 1997 magnetic resonance colonography (MRC) [7] were also proposed for colorectal screening. They have several advantages: minimally invasive, fast, detect extracolonic disease, and allow computer-aided detection. CT colonography has been recommended in the colorectal screening guidelines since 2008 [8].

With FDG-PET/CT another fascinating tool for colorectal screening is on the horizon. FDG-PET exploits the increased rate of glycolysis in tumour cells to detect diseases. FDG is a glucose analogue that is taken up by cellular glucose transport mechanisms. In the cell, FDG is phosphorylated by hexokinase. In most malignant cells, FDG-6-phosphate then becomes metabolically “trapped” intracellularly because of the relative lack of glucose-6-phosphatase activity in tumours. Thus, FDG accumulation mostly correlates with the grading and the degree of malignancy. Thus, in conjunction with CT, PET/CT brings the advantage of combining metabolic and structural information.

Because only 2.5 polyps in 1,000 develop into cancer per year [9, 10] and because size and shape are the only adequate predictive in vivo criteria for malignancy, PET information about the glucose metabolism could help in identifying relevant colorectal lesions that require polypectomy or resection [5]. Through neglecting PET-negative lesions unnecessary colonoscopies and polypectomies might possibly be prevented. The feasibility of combining PET and CT colonography into PET/CT colonography has been already shown in patients with full-dose CT for tumour staging [11, 12].

The purpose of this study was (a) to determine the performance of FDG-PET/CT in the detection of relevant colorectal neoplasms (adenomas ≥10 mm, with high-grade dysplasia or cancer) in relation to the CT dose and iodine contrast administration and (b) to find a standardised cut-off in PET which might serve as a basis for future computer-aided detection (CAD) applications.

Materials and methods

Patients

In a retrospective study approved by the institutional Ethics Committee, 4,004 consecutive FDG-PET/CT reports from 2,735 patients examined in the period from May 2005 to May 2009 at the University Hospital of Dresden were browsed for those patients who had either a colorectal cancer, a cancer of unknown primary (CUP) syndrome, or focal colorectal FDG uptake further evaluated by colonoscopy or sigmoidoscopy.

PET/CT protocol

PET/CT was performed from the skull base through to the mid-thigh on a 16-slice PET/CT (Biograph 16, Siemens Medical Solutions) and included:

1. Low-dose (<1 mSv) CT (10 mAs, 120 kV, 16×1.5 mm collimation, 0.42 s tube rotation time, 86 mm/s table feed) for attenuation correction, and/or
2. Normal-dose CT (100 mAs (care dose), 120 kV, 16×1.5 mm collimation, 0.75 s tube rotation time, 48 mm/s table feed) with contrast enhancement in the portal venous phase (370 mg/ml iodine concentration, 120 ml contrast volume, 3 ml/s flow, 55 s delay, 30 ml saline flush with 1.5 ml/s flow) and
3. PET following 74±12 min after the injection of 327±48 MBq FDG with 7–8 table positions each 3 min.

PET images were iteratively reconstructed with 5-mm-thick slices. CT images were reconstructed with 2.5-mm-thick slices.

The bowel was completely unprepared i.e. not cleansed, not distended and not relaxed with spasmolytics (Figs. 1, 2, 3). Only negative oral contrast material was given.

In order to increase the number of patients in the analysis also the PET/CT databank of the university hospital Frankfurt was browsed for patients fulfilling the inclusion criteria described above.

Interpretation

Examinations were analysed qualitatively on a per-segment basis and quantitatively on a per-lesion basis.

The qualitative analysis was blindly performed by two independent physicians—a radiologist experienced in CT colonography and less experienced in PET (R₁) and a nuclear medicine physician experienced in PET and less experienced in CT (R₂). They assessed the PET/CT on a commercially available workstation (Advantage Windows 4.4, General Electric) with two screens each with a quadrant display. The first screen showed only PET images: a rotating maximal intensity projection (MIP) (Fig. 1) in the upper left corner and the orthogonal (coronal, axial and sagittal) multiplanar reconstructions (MPRs) in the other three quadrants. The second screen showed three orthogonal MPRs of the PET/CT and a coronal CT in a lung window. For reviewing PET alone the second computer screen showing the PET/CT was shut down. This ensured that the PET was reviewed separately from the CT in order to compare the subjective PET reviewing with the cut-off-based PET analysis.

The rotating MIP of the PET was used to screen for increased FDG uptake in the abdomen (Fig. 1). Once
increased FDG uptake was found, the reviewer placed a cross-reference on the lesion which automatically showed the lesion on the three MPRs of the PET. By scrolling through the MPRs and following the course of the colon the reviewer had to decide if the lesion was in or outside the colon. If the lesion was considered to be in the colon, the reviewer had to assign the lesion to one of the six colonic segments (caecum, ascending, transverse and descending colon, sigmoid and rectum). Subsequently the reviewer had to rate the probability of the colonic segment being mass-positive on a five-point scale (1 = definitely negative, 2 = probably negative, 3 = equivocal, 4 = probably positive, 5 = definitely positive). Segments without increased FDG uptake were rated as definitely negative.

First PET was reviewed alone, then the second screen was turned on and PET was reviewed in combination with low-dose CT as PET/CT. CT was used to decide if the PET lesion was in or outside the colon and if the PET lesion had a sphincter, stool, collapsed bowel or an inflammation as a false-positive correlate. Finally low-dose CT was replaced by contrast-enhanced CT for evaluating contrast-enhanced PET/CT.

Measurements of Hounsfield units (HU) were used to prove stool by air inclusions (minimum HU<0) or a mass by a mean contrast enhancement (ΔHU = (HU<sub>with contrast</sub> - HU<sub>without contrast</sub>) > 20HU).

If a wall-adherent mass could be identified on CT (Fig. 3), its height and length were also measured vertically and tangentially with respect to the colonic wall. The larger diameter was used as size. If there was no correlate on CT, the PET lesion was considered a positive finding if it was regarded as a focal lesion (Figs. 1, 2, 3). In this case the size was obtained from colonoscopy or if totally resected, from the histological examination.

The quantitative analysis was performed for each visual colorectal FDG uptake and included the measurement of the maximum standardised uptake value (SUV<sub>max</sub>) and mean standardised uptake value (SUV<sub>mean</sub>) within a volume that contains only voxels with SUV ≥50% of SUV<sub>max</sub>. In addition, the volume of the FDG uptake was measured as so-called metabolic volume or volume of interest (VOI). Currently there is no rationale and no standardisation which border (isocountour) should be used to define the VOI. Therefore, we determined the VOI in relation to six isocontours defined by absolute thresholds (SUV=4, 7, 10) and relative thresholds depending on the SUV<sub>max</sub> (SUV=25%, 50%, 75% of SUV<sub>max</sub>). The value SUV=4 was chosen as the lowest limit for the absolute threshold because the physiological SUV<sub>max</sub> of the liver is in this range. The other cut-off values were equidistantly but otherwise arbitrarily chosen.
Fig. 2  Incidental focal colorectal FDG uptake in descending colon [carcinoma (arrow)] in a 72-year-old man on low-dose PET/CT (performed for evaluation of the glucose metabolism in a hepatocellular carcinoma (HCC) as surrogate for dedifferentiation/grading. The maximum standardised uptake value (SUV$\text{max}$) of 14.4 is a trigger for colonoscopy (Fig. 5).

Fig. 3  Incidental focal colorectal FDG uptake in the sigmoid colon [low-grade adenoma (arrow)] in a 66-year-old man on contrast-enhanced PET/CT performed for staging of oesophageal cancer. The maximum standardised uptake value (SUV$\text{max}$) of 9.1 is a trigger for colonoscopy (Fig. 5).
The SUV is normalised for activity injected per body weight according to the formula: SUV_{max/mean} = maximum/mean VOI activity [Bq/ml] / dose injected per patient’s weight [Bq/g] with g = ml for a tissue density of 1 g/ml.

Statistical analysis

Masses were defined as relevant if ≥10 mm in maximum diameter as measured by CT or by colonoscopy or histological examination, or if they revealed high-grade dysplasia, or were cancerous in the histological examination.

1. The inter-observer agreement in the decision to send the patient to colonoscopy (ratings: 3, 4, 5) or not (ratings: 1, 2) was determined by Cohen’s kappa. P values of kappa below 0.05 indicate a statistically significant difference from only chance agreement.

2. The performance of PET, low-dose PET/CT and contrast-enhanced PET/CT in detecting mass-positive segments was compared by the area under the receiver operating curve (ROC) for each reviewer as well as for both reviewers by averaging their ROC ratings to a common rating.

3. The per-segment performance of PET, low-dose PET/CT and contrast-enhanced PET/CT (sensitivity, specificity, negative predictive value (NPV), positive predictive value (PPV)) was determined with the dichotomised outcome of histological findings.

4. Univariate and multivariate logistic regression analyses were used to find cut-off parameters to discern the two outcome groups mentioned above.

5. The SUV_{max} were compared with non-parametric analysis of variance and Mann–Whitney U tests. Local p values for the tests done in pairs are given without adjustment. After applying Bonferroni adjustment to avoid an increasing probability of a type I error, p values stay below 0.05—the global alpha for this study.

6. Finally, PET performance characteristics were determined for a cut-off that included all carcinomas and adenomas with high-grade dysplasia (SUV_{max}≥5).

Statistical Analysis was performed by using a statistical software package (SPSS Inc., version 16.0, Chicago, USA).

Results

Patient demography

In total, 84 patients (18 female, 66 male) aged 41–91 (mean 65±10 years), who had a total colonoscopy (n=79) or a sigmoidoscopy (n=5) as standard of reference for in total (79 × 6 + 5 × 2) = 484 colonic segments, were included in this study. In one case, in which a tumour stenosis in the proximal rectum hindered a full colonoscopy, the postoperative colonoscopy was used as standard of reference for the colonic segments that were preoperatively not assessable. All sigmoidoscopies were performed instead of colonoscopies due to palliative situations.

Reasons for colonoscopy/sigmoidoscopy referral were: initial staging (n=14) or follow-up (n=5) of colorectal cancer, a CUP syndrome (n=15) or incidental focal colorectal FDG uptakes (n=50).

Patients with CUP syndrome

The 15 patients with CUP syndrome had malignant lesions at the following sites: liver (n=6), lymph nodes (n=4), bone (n=3), liver, lungs and bones (n=1) and seminal vesicle (n=1). Histological examination was available in 13 cases and revealed adenocarcinoma (n=8), epithelial cancer (n=3), anaplastic carcinoma (n=1) and remained unclear in one case (n=1) with osteolytic bone metastases. In 4 patients the hepatic lesions turned out to be the primary cancer (hepatocellular carcinoma (n=1) and cholangiocarcinoma (n=3)). In the remaining patients PET/CT found the primary cancer in 55% (6/11) at the following sites: oesophagus (n=1), colon (n=1), nasopharynx (n=1), tonsil (n=1), vulva (n=1) and urinary tract (n=1). Three primary malignancies (breast cancer (n=2) and prostate cancer (n=1)) were not visualised in PET. The origin of hepatic metastases in one patient and of osteolytic bone metastases in another patient remained unclear.

Incidental focal colorectal FDG uptakes

Incidental focal colorectal FDG uptakes were observed in 2.1% (in 50 out of 2,338 patients not scanned for colorectal cancer or CUP). In 50% (25/50) the incidental focal colorectal FDG uptake turned out to be a relevant mass on colonoscopy and even cancer in 16% (8/50).

Per-lesion analysis

In total, endoscopy revealed 59 relevant masses (36 adenomas and 23 carcinomas) in 43 out of 84 patients. Histological examination of the adenomas revealed in 3% (1/36) no dysplasia, in 69% (25/36) low-grade dysplasia, and in 28% (10/36) high-grade dysplasia (Fig. 4).

PET visibility for relevant masses totalled 90% (53/59); 83% (30/36) for relevant adenomas (mean size (range) 15±5 (9–25) mm) and 100% (23/23) for carcinomas (mean size (range) 35±20 (8–80) mm). PET failed to visualise 10% (6/59) of relevant masses. All masses not visualised on PET were adenomas. Three of the six FDG-negative adenomas were in one patient and showed high-grade dysplasia (two ≥10 mm, one 3 mm). The other three FDG-negative adenomas were in 3
different patients, measured ≥10 mm and revealed low-grade dysplasia. False-positive FDG uptakes totalled 45% (48/107), most (67%) had stool as correlate on CT and most (85%) were located in the caecum, sigmoid or rectum (Fig. 4). Using the CT component, the reviewers correctly identified 85% (41/48) of false-positive FDG uptakes and 15% (7/48) were falsely misinterpreted as masses.

The $SUV_{\text{max}}$ increases with the degree of malignancy, from adenomas with low- and high-grade dysplasia ($SUV_{\text{max}} = 9.7 \pm 6.9$ and $SUV_{\text{max}} = 11.6 \pm 4.1$) to carcinomas ($SUV_{\text{max}} = 12.9 \pm 6.8$) (Fig. 5). $SUV_{\text{max}}$ and $SUV_{\text{mean}}$ were found to be the best parameters for distinguishing false-positive (FP) from true-positive (TP) lesions. The $SUV_{\text{mean}}$ correlates with the $SUV_{\text{max}}$ ($r=0.97$, $n=107$ (59 TP and 48 FP)) but shows less difference than the $SUV_{\text{max}}$ between false-positives and masses. Therefore, the isocontour-independent $SUV_{\text{max}}$ was favoured as the cut-off.

In all carcinomas ($n=23$) and adenomas with high-grade dysplasia ($n=10$) the $SUV_{\text{max}}$ was ≥5 (Fig. 5). In order to include all carcinomas and adenomas with high-grade dysplasia this value was used as cut-off in the comparison between the reviewer-dependent and cut-off-based analysis.

### Fig. 4  Summary of findings

| Endoscopy (n=59) | PET (n=107 (101 positive (53 TP, 48 FP) + 6 FN)) |
|------------------|--------------------------------------------------|
| **Hyperplasia**  | TP 10% (1/10)                                    |
| **Adenoma**      | FP 45% (48/107)                                   |
| **Carcinoma**    | FN 10% (6/59)                                    |
| **Total**        |                                                   |
| **Hyperplasia**  |                                                   |
| **Adenoma**      |                                                   |
| **Carcinoma**    |                                                   |
| **Total**        |                                                   |

*adenomas ≥ 10 mm/with high-grade dysplasia.
†maximum size (mean ± SD (range)) measured on CT if visible; if not visible the size was obtained from the colonoscopy report.
‡TP=True-positive, FP=false-positive, FN=false negative.
Per-segment analysis (accuracy)

The performance of PET (subjective interpretation vs. cut-off-based analysis), low-dose PET/CT and contrast-enhanced PET/CT is summarised in Table 1: As reflected by the area under the curve low-dose PET/CT proved superior to PET but was not inferior to contrast-enhanced PET/CT. The use of an SUV_{max} ≥ 5 as a cut-off, which included all carcinomas and adenomas with high-grade dysplasia, resulted in a better per-segment sensitivity and

Table 1 Performance of FDG-PET/CT in the detection of relevant colorectal neoplasms (adenomas ≥10 mm, with high-grade dysplasia or cancer)

| Per Patient Segment Lesion (Fig. 4) | PET/CT PET PET/CT PET | Low dose Normal^a | Reviewer Cut-off (SUV_{max} ≥ 5) |
|------------------------------------|------------------------|------------------|--------------------------------|
| Incidence                          | 51% (43/84)            | 11% (54/484)     | 11% (42/398) 12% (49/404)      |
| Agreement^c                        | 89%                    | 91%              | 92%                          |
| AUC^d                              | 0.845                  | 0.882            | 0.875                        |
| R_1                                | 0.857                  | 0.887            | 0.888                        |
| R_1 + R_2                          | 0.899                  | 0.925            | 0.929                        |
| Sensitivity^e                      | 91% (39/43)            | 81% (44/54)      | 89% (48/54) 76% (32/42) 82% (40/49) 90% (53/59) 94% (50/53) |
| Specificity^e                      | 80% (33/41)            | 93% (399/430)    | 93% (401/430) 97% (345/356) 97% (344/355) – 35% (17/48) |
| NPV^e                              | 89% (33/37)            | 98% (399/409)    | 99% (401/407) 97% (345/355) 98% (344/353) – 85% (17/20) |
| PPV^e                              | 83% (39/47)            | 59% (44/75)      | 62% (48/77) 74% (32/43) 78% (40/51) 52% (53/101) 62% (50/81) |
| Accuracy^e                         | 86% (72/84)            | 92% (443/484)    | 93% (449/484) 95% (377/398) 95% (384/404) – 66% (67/101) |

^a Normal:=contrast enhanced with full CT dose

^b Segments with a standard of reference = 70 × 6 (colonoscopy) + 5 × 2 (sigmoidoscopy)

^c In the decision to send the patient for colonoscopy (ratings: 3,4,5) or not (ratings: 1,2) (kappa=0.630; 0.605; 0.681; p=0.000)

^d Area under the curve (AUC) of the receiver operating characteristic curve (ROC) separate for each reviewer (R_i) and for both reviewers (R_1+R_2) with averaged ratings

^e Obtained from the averaged ratings of two independent reviewers or via the cut-off SUV_{max} ≥ 5

^f 3 adenomas with low-grade dysplasia 12±2 mm in size would have been additionally missed with the cut-off SUV_{max} ≥ 5
negative predictive value than the average PET and PET/CT reviews (sensitivity 89% vs. 81% and 76–82%; NPV 99% vs. 98% and 97–98%) (Table 1).

Discussion

There is compelling evidence to support screening average-risk individuals aged over 50 to detect and prevent colorectal cancer [2, 3, 8, 13]. By sparing bowel cleansing and distension, by displaying only relevant lesions requiring polypectomy or resection, by taking advantage of computer-aided detection via a standardised cut-off, and by increasing the accuracy in detecting extra-colonic pathological features, PET/CT could surpass CT and MR colonography for colorectal screening.

Clinical impact

Multiple studies have already documented the value of PET/CT for primary staging, restaging, and follow-up of patients with colorectal cancer [14, 15]. Based on its therapeutic impact, its first-line use is increasingly recommended for staging and restaging [15]. For detecting recurrence of colorectal cancer, PET/CT can be more sensitive than tumour markers, so that surveillance of asymptomatic and even tumour-marker-negative patients with PET/CT seems plausible [14, 16–18], in particular when taking into account that PET/CT allows for comprehensive “TNM” follow-up in one examination that is probably more accurate than CT and colonoscopy together. Replacing CT and colonoscopy by PET/CT also seems plausible for evaluation of asymptomatic average-risk patients who present with raised carcinoembryonic antigen (CEA) which indicates a malignancy in 20% with 75% outside the colon [19].

The study suggests that colorectal cancer is always visualized in PET, here with a mean SUV max of 12.9±6.8 (range 5.7–29.6) (n=23) (Fig. 5) in accordance with the literature (SUV max = 12.6 ± 4.9) (n=51) [20–24].

We found that the cut-off-based PET analysis is more accurate than the reviewer-dependent analysis (Table 1). This finding in conjunction with the low incidence of focal colorectal FDG uptakes 2.1% (literature, 2.2% (628 out of 28,253 patients)) but their high predictive value for a mass of 62% (here with the cut-off SUV max≥5) (literature, 73% (254 out of 349))—of which 46% (literature, 33%) were even cancer [20–22, 25–32]—indicates the recommendation that all patients with focal colorectal FDG uptakes with SUV max≥5 should automatically undergo a colonoscopy. In other words the overall rate of false-positive FDG uptakes resulting in unnecessary colonoscopy in 0.6% should be accepted for the benefit of detecting masses in 1.6% including even cancer in 0.5% [20–22, 25–32]—in particular if colonoscopy is recommended for screening anyway.

In our study PET/CT incidentally detected additional colorectal cancer in 0.3% (8/2,338) (Figs. 1, 2, 3) and found the primary cancer in the patients with CUP syndrome in 55% (6/11). Ishimori et al. [33] found colorectal cancer as an additional primary malignancy in 0.2% (4/1,912) and other proven carcinomas in 1% including cancer in the head and neck (n=1), thyroid (n=6), lung (n=7), lung and thyroid (n=1), oesophagus (n=2), breast (n=2) and bile duct (n=1) [33]. We did not evaluate the value of PET/CT in detecting relevant extra-colonic pathologies. But we could demonstrate its value in detecting the primary cancer in patients with CUP syndrome as a surrogate for its potential in detecting relevant extra-colonic pathologies.

PET/CT performed as PET/CT colonography on a cleansed and distended colon [11] as well as on a non-cleansed, only distended colon [12] is also feasible. This has been proposed for patients with an incomplete colonoscopy. Under optimal conditions in a screening setting with a fully cleansed and distended colon, CT colonography is so accurate that the additional value of PET is minimal. Therefore, we evaluated the value of PET/CT in a worst-case scenario i.e. in a non-cleansed and non-distended colon imaged with minimal CT-dose and without contrast material.

Screening issue

Acceptance and compliance

Although the average lifetime risks of diagnosing and dying of colorectal cancer are 5.7% and 2.5%, respectively [34], and although a majority of cases of colorectal cancer can be prevented with colonoscopic removal of the precursor adenomatous polyp [2–4], compliance with colonoscopy is abysmal. Recently, a regional colonoscopy screening programme demonstrated a disappointing low participation rate of 1.5% despite the benefits and quality of service [35]. On the other hand, the programme underlined the efficacy of screening. Colorectal masses were found in 26% (14,140 out of 54,491) of asymptomatic participants. Cancer was found in 1.3% (692 out of 54,491).

In a CT colonography screening study including 1,452 subjects, the participation rate was 28% [36]. CT colonography is considered less painful and less difficult than colonoscopy and is preferred over colonoscopy [37–39]. Also MR colonography with limited bowel preparation was preferred over colonoscopy due to limited bowel preparation and less pain [40]. However, discomfort associated with cleansing and air filling is still an issue in colonography [36–38], probably impacting compliance with an interval screening programme.

A non-invasive method without cleansing, colon distension and contrast material might possibly enhance compliance with a screening programme. Thus, especially in the case of colorectal cancer with a dwell time of 10 years in the adenoma–carcinoma sequence [9], compliance with a screening programme may compensate for less sensitivity of a single interval examination. Thus, a higher participation rate in a PET/CT programme com-
bined with a high accuracy in detecting relevant extra-colonic findings could compensate for the low PET sensitivity in the detection of small polyps—if small polyps are relevant at all [10].

In CT colonography, relevant extra-colonic findings requiring subsequent medical or surgical interventions were observed in 3.2% (109/3,376) in a screening population [41–43]. Typical examples of important findings are aortic aneurysms, solid renal or hepatic masses, adrenal masses, suspicious lung nodules, hydronephrosis, lymphadenopathy, and ovarian cysts [41, 42, 44]. PET/CT is more specific than contrast-enhanced CT in characterising hepatic masses, adrenal masses, lung nodules and ovarian cysts. Thus, it is more cost-effective than CT colonography for which a mean cost of US $27±8 per patient was calculated for further evaluation of extra-colonic findings [41–43, 45, 46].

Of course, currently the limited availability of PET/CT and its high costs hinder its use for screening. However, if the costs for a non-invasive, 5-min PET/CT examination are lower than those for the sum of the examinations needed to exclude the same amount of cancer entities in the early stage (e.g. MRI, CT, endoscopies for the hollow organs, mammography, inspection for melanoma), the demand for PET/CT as an all-in-one (multiorgan screening) examination might increase.

**Target**

It is generally accepted that in 80–85% of cancer cases, adenomas constitute the precursors for colorectal cancer [2, 3, 9] and that the progression from adenoma to carcinoma takes 10 years or more [9, 10]. Thus, removal of adenomas at regular intervals in an appropriate time frame constitutes a simple and effective cancer prophylaxis. The fact that the prevalence of polyps is high (30–50%) after age 50 years, increases with age, and that only approximately 3% of the adenomas become malignant [9, 10], render the introduction of a cut-off value in polyp screening reasonable to avoid unnecessary polypectomies.

In CT colonography, the cut-off is related to size and amount relative to 10 mm [26–28]. The sensitivity of PET/CT in visualising polyps ≤10 mm is only 21% (46 out of 219), and the 66% (163 out of 247) sensitivity in detecting masses >10 mm is disappointing compared with that of CT colonography (sensitivity 94%) [24, 27, 30, 47–49]. Despite the high molecular sensitivity of PET for the tracer (10–11–10–12 mole/L), smaller polyps can be negative on PET if their signal is spatially and temporally averaged to normal in the 5 mm³ image voxel and 3-min acquisition time per bed position (partial volume artefact). Hence, it is clear why PET fails to visualize smaller polyps whose signal is blurred in the colonic peristalsis and averaged with that of the signal void of surrounding air in the colon. In this study with improved spatial resolution (4.5 mm in the axial plane), the detection rate for polyps ≥10 mm was 83% (30/36). Current PET/CT provides a higher spatial resolution (2.5 mm) and detector gain (detected counts per second and applied activity (currently 9.1 kcounts/sMBq)) as well as a faster scanning (5 min per whole body), so that detecting smaller polyps may increase as technology progresses and partial volume effects decrease. But the spatial resolution is limited by the linear range of the random walk of the positron, which is a mean of 0.2 mm (maximum 2.4 mm) in the case of ¹⁸F. However, lower spatial resolution can be compensated by a higher FDG uptake (hot spot phenomena) so that smaller neoplasms will be detected if their SUVmax is large enough to be differentiated from the background noise (Figs. 1, 2, 3).

Smaller, non-growing and therefore non-glucose-consuming polyps are usually not visible on PET [24]. Thus, with metabolic information, PET/CT is inherently more promising than CT colonography in identifying polyps at risk of malignant transformation or already transformed to cancer. Van Kouwen et al. [50] showed in 24 patients with familial adenomatous polyposis (FAP) that the metabolic PET information identified FAP patients requiring additional examinations to rule out cancer and justified in others a more conservative approach. Other studies also showed a difference in the FDG uptake between polyps and cancer (SUVmax: 9.1 ± 3.6 for polyps (n = 88) vs. 12.6 ± 4.9 for carcinomas (n = 51)) [20–24]. This study confirms the correlation between the degree of malignancy and glycolysis rate reflected by SUVmax (Fig. 5). The correlation between the degree of malignancy and glycolysis provides the rationale for an SUVmax-based cut-off.

**Computer-aided detection**

Computer-aided detection also requires a cut-off. Using a cut-off (SUVmax≥5), that includes all carcinomas and all adenomas with high-grade dysplasia (Fig. 5), resulted in a higher sensitivity and negative predictive value than the reviewer-dependent analysis of the contrast-enhanced PET/CT (sensitivity 89% vs. 82%, NPV 99% vs. 98%) (Table 1). However, the lower specificity of PET in comparison with PET/CT (93% vs. 97%) (Table 1) demonstrates that the PET findings should be still anatomically correlated with the CT to better identify false-positives as stool, gastric or anal sphincters or parts of the urinary system. Administration of contrast did not improve the accuracy (95%) and specificity (97%) of PET/CT (Table 1). Thus, for screening purposes contrast media is not needed and in the case of an equivocal finding in the colorectum the patient should be sent for colonoscopy instead of receiving contrast material and a second CT scan.

We tested different PET values and their combinations for separating true-positives (TP) from false-positives (FP). But the metabolic volumes (VOI) as well as the ratios SUVmax/mean/metabolic volumes, reflecting a kind of density, were inferior to the SUVmax in the differentiation between TP and FP. In principle, the focality of an FDG uptake visualised on 2D maximum intensity projections...
SUVmax criteria (e.g. high value and homogeneous distribution) can possibly also be identified by a human interface. But the urinary system as the only physiological cause of increased FDG uptake in the abdomen needs to be excluded by an abdominal FDG uptake over a certain cut-off. Then, initiating a malignancy in 20 years. The radiation risk – 0.012 mSv/MBq × 370 MBq (PET dose) [61]. Cancer is responsible for death in more than 25% of the population in industrialised nations [62]. The probability of detecting cancer increases with age while the probability of dying from radiation-induced cancer decreases with age due to the latency period of 20–30 years. Therefore, the individual benefit-to-cost ratio of PET/CT screening increases with age. In the worst case, if both the radiation-induced cancer mortality (0.024%) and the natural cancer mortality (25%) are not age-related, to be justified PET/CT needs to prevent more than 0.6% of the natural 25% of cancer mortality.

Limitation and future work

The study is retrospective. Further prospectively designed studies should clarify:

- If omission of oral contrast reduces the FDG uptake in the normal colonic wall and its excretion into stool (direct or via dissociation of FDG-loaded mucosa cells) [63].
- If the cut-off is dependent on the scanner type and requires a cross-calibration between different scanners [64].
- If an intrinsic normalisation to the mean SUV of the liver improves the accuracy of the cut-off [65], and
- If low dose, non-enhanced PET/CT is more cost-effective than CT in identifying (detecting and classifying) relevant extra-colonic pathological features [66].

Another limitation of this retrospective study is the selection bias. Only patients with a high likelihood of being further evaluated with colonoscopy were filtered out of the PET database of 4,004 reports. Thus, the database was only browsed for patients referred for initial staging or follow-up of colorectal cancer or for further evaluation of a CUP syndrome or incidental focal colorectal FDG uptakes. The other, mostly oncological PET patients were unlikely to undergo additional screening colonoscopy within the next 3 months after the PET/CT. Therefore, we limited the search only to the subgroup described above and did not check if other PET patients coincidentally underwent a colonoscopy. However, by including patients with CUP syndrome as a “normal collective” (without a colorectal mass), dividing the colon into six segments, considering each segment as independent and performing a per-segment analysis, we sought to lower the incidence (43/84 (51%) per patient vs. 54/484 (11%) per segment) and thereby to minimise any bias that might be associated with the patient selection. A prospective study including a normal collective undergoing PET/CT followed by colonoscopy would overcome the selection bias. However, the meaning of the SUVmax as cut-off should not be biased by the patient selection.
Conclusion

FDG-PET/CT provides promising accuracy for colorectal mass detection. Low dose and lack of iodine contrast do not impact the accuracy. A standardised PET cut-off (e.g. SUVmax ≥ 5) improves the accuracy.

Prospective studies with more polyps and improved PET technology seem to be warranted—not only to obtain a test data set for finding a better cut-off, but also to figure out if PET/CT is sufficient for ruling out relevant colorectal neoplasms.

Acknowledgements The authors like to thank the German Federal Ministry of Education and Research (BMDF) for providing the PET/CT (Contract 03 ZIK 04).

Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

References

1. Jemal A, Siegel R, Ward E et al (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71–96
2. Vogelstein B, Fearon ER, Hamilton SR et al (1988) Genetic alterations during colorectal-tumor development. N Engl J Med 319:525–532
3. Toribara NW, Sleisenger MH (1995) Screening for colorectal cancer. N Engl J Med 332:861–867
4. Winawer SJ, Zauber AG, Ho MN et al (1993) Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 329:1977–1981
5. Winawer SJ, Fletcher RH, Miller L et al (1995) Genetic alterations during colorectal-tumor development. N Engl J Med 332:861–867
6. Hara AK, Johnson CD, Reed JE et al (1996) Detection of colorectal polyps by computed tomographic colonography: feasibility of a novel technique. Gastroenterology 110:284–290
7. Luboldt W, Bauerfeind P, Steiner P, Fried M, Krestin GP, Debatin JF (1997) Preliminary assessment of three-dimensional magnetic resonance imaging for various colonic disorders. Lancet 349:1288–1291
8. Levin B, Lieberman DA, McFarland B et al (2008) Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 134:1570–1595
9. Eide TJ (1991) Natural history of adenomas. World J Surg 15:3–6
10. Nusko G, Mansmann U, Partzsch U et al (1997) Invasive carcinoma in colorectal adenomas: multivariate analysis of patient and adenoma characteristics. Endoscopy 29:626–631
11. Veit-Haibach P, Kuehle CA, Beyer T et al (2006) Diagnostic accuracy of colorectal cancer staging with whole-body PET/CT colonography. JAMA 296:2590–2600
12. Nagata K, Ota Y, Okawa T, Endo S, Kudo SE (2008) PET/CT colonography for the preoperative evaluation of the colon proximal to the obstructive colorectal cancer. Dis Colon Rectum 51:882–890
13. Brenner H, Hoffmeister M, Brenner G, Altenhofen L, Haug U (2009) Expected reduction of colorectal cancer incidence within 8 years after introduction of the German screening colonoscopy programme: estimates based on 1,875,708 screening colonoscopies. Eur J Cancer 45:14–18
14. Shen YY, Liang JA, Chen YK, Tsai CY, Kao CH (2006) Clinical impact of 18F-FDG-PET in the suspicion of recurrent colorectal cancer based on asymptptomatically elevated serum level of carcinoembryonic antigen (CEA) in Taiwan. Hepatogastroenterology 53:348–350
15. Vriens D, de Geus-Oei LF, van der Graaf WT, Oyen WJ (2009) Tailoring therapy in colorectal cancer by PET-CT. Q J Nucl Med Mol Imaging 53:224–244
16. Chen LB, Tong JL, Song HZ, Zhu H, Wang YC (2007) (18)F-DG PET/CT in the suspicion of recurrent colorectal cancer. World J Gastroenterol 13:5025–5029
17. Vriens D, de Geus-Oei LF, van der Graaf WT, Oyen WJ (2009) Tailoring therapy in colorectal cancer by PET-CT. Q J Nucl Med Mol Imaging 53:224–244
18. Chen LB, Tong JL, Song HZ, Zhu H, Wang YC (2007) (18)F-DG PET/CT in the suspicion of recurrent colorectal cancer. World J Gastroenterol 13:5025–5029
19. Sorensen N, Jensen A, Wille-Jørgensen P et al (2009) Strict follow-up programme including CT and F-FDG-PET after curative surgery for colorectal cancer. Colorectal Dis 11:11
20. Tan E, Gouvas N, Nicholls RJ, Ziprin P, Xynos E, Tekkis PP (2009) Diagnostic precision of carcinoembryonic antigen in the detection of recurrence of colorectal cancer. Surg Oncol 18:15–24
21. Lim YK, Kam MH, Eu KW (2009) Carcinoembryonic antigen screening: how far should we go? Singapore Med J 50:862–865
22. Gutman F, Alberini JL, Wartski M et al (2005) Incidental colonic focal lesions detected by FDG PET/CT. AJR Am J Roentgenol 185:495–500
23. Nakajo M, Jinnouchi S, Tashiro Y, Shirahama H, Sato E, Koryama C (2009) Effect of clinicopathologic factors on visibility of colorectal polyps with FDG PET. AJR Am J Roentgenol 192:754–760
24. Ravizza D, Bartolomei M, Santoro L et al (2009) Positron emission tomography for the detection of colorectal adenomas. Dig Liver Dis 32:28–32
25. Zhuang H, Hickeson M, Chacko TK et al (2002) Incidental detection of colon cancer by FDG positron emission tomography in patients examined for pulmonary nodules. Clin Nucl Med 27:628–632
26. Agress H Jr, Cooper BZ (2004) Detection of clinically unexpected malignant and premalignant tumors with whole-body FDG PET: histopathologic comparison. Radiology 230:417–422
27. Kamel EM, Thumshirn M, Truninger K et al (2004) Significance of incidental 18F-FDG accumulations in the gastrointestinal tract in PET/CT: correlation with endoscopic and histopathologic results. J Nucl Med 45:1804–1810
28. Pandit-Taskar N, Schoder H, Gonen M, Larson SM, Yeung HW (2004) Clinical significance of unexplained abnormal focal FDG uptake in the abdomen during whole-body PET. AJR Am J Roentgenol 183:1143–1147
29. Even-Sapir E, Lerman H, Gutman M et al (2006) The presentation of malignant tumours and pre-malignant lesions incidentally found on PET-CT. Eur J Nucl Med Mol Imaging 33:541–552
30. Hernandes AK, Robson NK, Hickish T, Talbot RW (2008) Colorectal tubulovillous adenomas identified on fluorodeoxyglucose positron emission tomography/computed tomography scans. Colorectal Dis 10:386–389
31. Lee ST, Tan T, Poon AM et al (2008) Role of low-dose, noncontrast computed tomography from integrated positron emission tomography/computed tomography in evaluating incidental 2-deoxy-2-[F-18]fluoro-D-glucose-avid colon lesions. Mol Imaging Biol 10:48–53

32. Lee JC, Hartnett GF, Hughes BG, Ravi Kumar AS (2009) The segmental distribution and clinical significance of colorectal fluorodeoxyglucose uptake incidentally detected on PET-CT. Nucl Med Commun 30:333–337

33. Ishimori T, Patel PV, Wahl RL (2005) Epidemiology and quality control of 245,000 outpatient colonoscopies. Dtsch Arztebl 105:434–440 (www.aerzteblatt-international.de)

34. Edwards JT, Mendelson RM, Fritschi L et al (2004) Colorectal neoplasia screening with CT colonography in average-risk asymptomatic subjects: community-based study. Radiology 230:459–464

35. Mansman U, Crispin A, Henschel V et al (2008) Economic impact of extracolonic findings at computed tomographic colonography. J Comput Assist Tomogr 32:497–503

36. van Kouwen MC, Nagengast FM, Jansen JB, Owen WJ, Drenth JP (2005) 2-(18F)-fluoro-2-deoxy-D-glucose positron emission tomography detects clinical relevant adenomas of the colon: a prospective study. J Clin Oncol 23:3713–3717

37. Yasuda S, Fujii H, Nakahara T et al (2001) 18F-FDG PET detection of colonic adenomas. J Nucl Med 42:898–902

38. van Kouwen MC, Jansen JB, Owen WJ, Drenth JP (2005) 2-(18F)-fluoro-2-deoxy-D-glucose positron emission tomography detects clinical relevant adenomas of the colon: a prospective study. J Clin Oncol 23:3713–3717

39. Friedland S, Soetikno R, Carlisle M, Welch TJ (2000) Incidental extracolonic findings at CT colonography. Radiology 215:353–357

40. Taylor SA, Halligan S, Saunders BP, Bassett P, Vance M, Bartram CI (2003) Acceptance by patients of multidetector CT colonography compared with barium enema examinations, flexible sigmoidoscopy, and colonoscopy. AJR Am J Roentgenol 181:913–921

41. Gluecker TM, Johnson CD, Wilson LA et al (2003) Extracolonic findings at CT colonography: evaluation of prevalence and cost in a screening population. Gastroenterology 124:911–916

42. Yee J, Kumar NN, Godara S et al (2005) Extracolonic abnormalities discovered incidentally at CT colonography in a male population. Radiology 236:519–526

43. Pickhardt PJ, Hansoe M, Vanness DJ et al (2008) Unsuspected extracolonic findings at screening CT colonography: clinical and economic impact. Radiology 249:151–159

44. Pickhardt PJ, Choi JR, Hwang I et al (2003) Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic adults. N Engl J Med 349:2191–2200

45. Flicker MS, Tsoukas AT, Hazra A, Dachman AH (2008) Economic impact of extracolonic findings at computed tomographic colonography. J Comput Assist Tomogr 32:497–503

46. Hara AK, Johnson CD, MacCarty RL, Welch TJ (2000) Incidental extracolonic findings at CT colonography. Radiology 215:353–357

47. Yasuda S, Fujii H, Nakahara T et al (2001) 18F-FDG PET detection of colonic adenomas. J Nucl Med 42:898–902

48. van Kouwen MC, Jansen JB, Owen WJ, Drenth JP (2005) 2-(18F)-fluoro-2-deoxy-D-glucose positron emission tomography detects clinical relevant adenomas of the colon: a prospective study. J Clin Oncol 23:3713–3717

49. Friedland S, Soetikno R, Carlisle M, Welch TJ (2000) Incidental extracolonic findings at CT colonography. Radiology 215:353–357

50. van Kouwen MC, Jansen JB, Owen WJ, Drenth JP (2005) 2-(18F)-fluoro-2-deoxy-D-glucose positron emission tomography detects clinical relevant adenomas of the colon: a prospective study. J Clin Oncol 23:3713–3717

51. Hays MT, Watson EE, Thomas SR, Stabin M (2002) MIRD dose estimate report no. 19: radiation absorbed dose estimates from (18)F-FDG. J Nucl Med 43:210–214

52. Becker N, Wahrenrod J (1998) Krebsatlases der Bundesrepublik Deutschland 1981–1990. Springer, Berlin. http://www.dkfz-heidelberg.de/de/krebstatlas/gesamt/mort_2.html. Accessed 24 Sept 2009

53. Hartmann T, Voss K, Schuchardt J et al (2003) The value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in carcinoma of an unknown primary: diagnosis and follow-up. Nucl Med Commun 24:1403–1408

54. Yasuda S, Ide M, Fujii H et al (2000) Application of positron emission tomography imaging to cancer screening. Br J Cancer 83:1607–1611

55. Chen YK, Ding HJ, Su CT et al (2004) Application of PET and PET/CT imaging for cancer screening. Anticancer Res 24:4103–4108

56. Minamimoto R, Senda M, Uno K et al (2007) Performance profile of FDG-PET and PET/CT for cancer screening on the basis of a Japanese nationwide survey. Ann Nucl Med 21:481–498

57. Kojima S, Zhou B, Teramukai S et al (2007) Cancer screening of healthy volunteers using whole-body 18F-FDG-PET scans: the Nishidai clinic study. Eur J Cancer 43:1842–1848

58. Nishizawa S, Kojima S, Teramukai S et al (2009) Prospective evaluation of whole-body cancer screening with multiple modalities including [18F] fluorodeoxyglucose positron emission tomography in a healthy population: a preliminary report. J Clin Oncol 27:1767–1773

59. Hays MT, Watson EE, Thomas SR, Stabin M (2002) MIRD dose estimate report no. 19: radiation absorbed dose estimates from (18)F-FDG. J Nucl Med 43:210–214

60. Becker N, Wahrenrod J (1998) Krebsatlases der Bundesrepublik Deutschland 1981–1990. Springer, Berlin. http://www.dkfz-heidelberg.de/de/krebstatlas/gesamt/mort_2.html. Accessed 24 Sept 2009

61. Otsuka H, Graham MM, Kubo A, Nishitani H (2005) The effect of oral contrast on large bowel activity in FDG-PET/CT. Ann Nucl Med 19:101–108

62. Boellaard R, Oyen WJ, Hoekstra CJ et al (2008) The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multicentre trials. Eur J Nucl Med Mol Imaging 35:2320–2333

63. Paquet N, Albert A, Foidart J, Hustinx R (2003) Application of PET and PET/CT in neoplasia in asymptomatic adults. N Engl J Med 349:2191–2200

64. Boellaard R, Oyen WJ, Hoekstra CJ et al (2008) The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multicentre trials. Eur J Nucl Med Mol Imaging 35:2320–2333

65. Paquet N, Albert A, Foidart J, Hustinx R (2004) Within-patient variability of (18)F-FDG: standardized uptake values in normal tissues. J Nucl Med 45:784–788

66. Hasson C, Pickhardt PJ, Laghi A et al (2009) Impact of whole-body CT screening on the cost-effectiveness of CT colonography. Radiology 251:156–165

67. Shen YY, Su CT, Chen GJ, Chen YK, Liao AC, Tsai FS (2003) The value of 18F-fluorodeoxyglucose positron emission tomography with the additional help of tumor markers in cancer screening. Neoplasma 50:217–221